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Normal hematopoiesis is associated with functional integrity of the BM microenvironment comprising a small number of mesenchymal stem cells (MSCs), 1 mesenchymalderived stromal cells (MDSCs) 2 and, to lesser extent, endothelial cells (ECs). 3 Microvascular endothelium is a component of the BM microenvironment producing cytokines that regulate proliferation and differentiation of hematopoietic progenitors. 3, 4 Porcine microvascular endothelial cell stromal layers and embryonic aorta-gonadmesonephro region-derived endothelium are able to support the initial expansion of human hematopoietic progenitor cells, and have the ability to protect hematopoietic progenitors from extensive differentiation. [3] [4] [5] There is increasing evidence that EC residing in the BM can contribute to maintenance and proliferation of stem/ progenitor cells. They also seem to be implicated in the regulation of stem cells trafficking during progenitor cell mobilization and homing, but the mechanisms involved are not yet completely understood. 5, 6 There is also evidence for circulating EC that are probably mobilized in response to endogenous stimuli or exogenously by cytokine therapy. 7 However, most studies on stromal regulation of hematopoiesis derive from investigation of BM fibroblasts while few studies have investigated the in vitro characteristics and the role of human BM endothelial cells in hematological diseases. 3 Recent reports have shown that ECs are important not only in normal hematopoiesis but also in leukemogenesis. Several studies have recently stressed the role of endothelial cells in the angiogenesis process of many tumors including leukemias, 8, 9 where it has been demonstrated that leukemic cells have intimate interactions with BM endothelial cells, thus suggesting the concept that hematopoietic stem cells could promote angiogenesis. The contact between endothelial cells and normal or malignant hematopoietic cells is mediated by adhesion molecules as well as by some soluble angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor-bFGF. VEGF is currently considered to be the most endothelium-specific angiogenic factors, and a correlation between the detection of VEGF and clinical outcome has been explored. [8] [9] [10] The microvessel density (MVD) of BM cells, as assessed by anti-factor-VIII monoclonal antibody (MoAb) staining method, has been found to be significantly increased in multiple myeloma (MM), 11 non-Hodgkin's lymphoma (NHL), 12 acute myeloid leukemia (AML), 13 acute lymphoblastic leukemia (ALL) 14 and recently in myelodysplastic syndromes 15 as compared with that of control samples. Because an in vitro method for the analysis and enumeration of endothelial colonies was lacking, we have recently described a rapid and feasible assay to detect BM endothelial cell colonies (CFU-En) that spontaneously grow in the human BM of multiple myeloma (MM) patients. 16 In the same report, we provided evidence in favor of an association between in vitro CFU-En overgrowth and plasma cells proliferation, suggesting a role of these cells in MM angiogenesis process, that may be parallel to that observed in vivo. However, no data are available in the literature regarding the possible role played by BM endothelial cells in hematological disorders such as NHL. 17 Based on these considerations, the distribution and the immunophenotypical features of CFU-En colonies was also evaluated in the BM of NHL patients with the aim of clarifying whether any difference in CFU-En number could be correlated with (1) the type of the neoplastic clone (T or B cell); (2) the phase of the disease (onset, remission phase after chemotherapy, early and late phases after peripheral blood stem cell transplantation (PBSCT); (3) bone marrow involvement at diagnosis; (4) the grade of the lymphoma (high-intermediate-low grade); (5) the age and the sex; (6) the type of treatment employed (chemotherapy, radiotherapy, PBSCT); (7) number of BM hematopoietic (CFU-C) and mesenchymal (CFU-F) progenitor cells. ), five on MACOP-B, three on ESHAP, two on CNOP/CHOP. BM samples were collected before the mobilization regimen and at different time periods after auto-PBSCT (I: 1-4 months, II: 5-9 months, III: 10-15 months; IV: 15-21 months, V: 421 months). In total, 10 patients relapsed after PBSCT. Normal control samples were obtained, after informed consent, from proximal epiphysis of femur from eight healthy subjects which underwent major orthopedic surgical intervention (mean age 56.2, range 49-59 years).
Materials and methods

Patients
CFU-En cell cultures
The BM specimens were obtained, after informed consent, by aspiration with Jamshidi needle; 3 ml from each fresh sample were gently passaged through a 22 gauge needle in order to homogenize the BM particles. 2 Cultures were performed in triplicate. At weekly intervals, half of the supernatant medium and suspension cells were removed and replaced with fresh medium. At the 15th day, using an inverted microscope (10 Â , WilovertWill Wetzlar, Germany), CFU-En detection was carried out as previously described. 16 After 20 days of culture, in order to assess the proliferation capacity, the endothelial cells were subcloned and plated with M199 Glutamax I (Gibco BRL, Life Technology, Paisley, Scotland, UK) supplemented with 20% of fetal calf serum (StemCell Technologies Inc., Vancouver, BC, Canada), 1% penicillin/ streptomycin and 1% L-glutamine (Hyclone Europe Ltd., Cramlington, UK). Endothelial cell growth supplement (ECGS, 75 mg/ml, from bovine neural tissue) and vascular endothelial growth factor (VEGF, 30 ng/ml; both from Sigma-Chemical, St Louis, MO, USA) were also added to the medium.
Immunophenotypic characteristics of CFU-En colonies
Primary human BM endothelial colonies (CFU-En) from NHL patients cultured in Petri dishes were studied using an immunohistochemical technique in combination with either polyclonal or monoclonal antibodies. These studies were performed in situ after medium removal: briefly Petri dishes were washed in pre-warmed Tris-buffered saline (TBS) (pH Table 2 .
Short-term colony forming unit-fibroblast (CFU-F) assay
Patient's microenvironment was investigated by performing the CFU-F assay, as previously reported by CastroMalaspina. 18 Briefly, 1 Â 10 6 /ml BMMNCs were resuspended in LTC medium, containing Iscove's-modified Dulbecco's medium (IMDM) (Euroclone Ltd., Paington, UK) 350 mosm/kg supplemented with pre-selected 12.5% fetal bovine serum (FBS) 12.5% horse serum (HS) (both sera from Stem Cell Technologies, Vancouver, BC, Canada), 1% L-glutamine (Euroclone), 1% penicillinstreptomycin (Euroclone) and plated on 35-mm Collagen I Cellware bio-coated Petri-dishes (Becton-Dickinson Labware, Bedford, MA, USA). The medium was changed every week and the cultures were incubated at 371C in a humidified atmosphere supplemented with 5% CO 2 . At the 14th day of culture, cells were washed with PBS, fixed in methanol for 4 min and stained with May-GrunwaldGiemsa. Fibroblasts aggregates with more than 50 cells were scored as CFU-F. All determinations were performed in duplicate and expressed as mean values. The mean number of CFU-F in the different groups of NHL patients, and assessed in the different time periods before and after autologous transplantation are reported in Table 3 .
Short-term hematopoietic colony assays from BM samples BMMNC were isolated by centrifugation on Lympholyte-H gradient, washed in PBS and plated in triplicate at 1 Â 10 5 cells density in 35-mm Petri dishes (Pbi, Milan, Italy) in 1.1 ml of a methylcellulose semisolid medium (Methocult H4434, Stem Cell Technologies Inc., Vancouver, Canada). Petri dishes were incubated at 371C in a fully humidified atmosphere with 5% CO 2 and scored at day 14 under inverted microscope (Wilovert-Will, Wetzlar, Germany) for the presence of hematopoietic progenitor colonies (CFU-C): colony-forming-unit granulocyte, macrophage (CFU-GM), burst-forming-unit erythroid (BFU-E), multilineage colony-forming unit (CFU- GEMM). The mean values of BM hematopoietic progenitors from NHL patients in relation to the different time periods before and after autologous transplantation are reported in Table 3 .
Statistical analysis
CFU-En numbers were compared using nonparametric statistics (Wilcoxon's test) in the different NHL categories grouped according to the following characteristics: (1) 
Results
Cell culture
Long-term bone marrow cultures from patients and controls were examined for the presence of endothelial colonies. After a few days of long-term culture the adherent bone marrow fraction was mainly composed of hematopoietic cells, but within 8-10 days the presence of small round-shaped endothelial cells, growing in typical cobblestone fashion forming little clusters, became more evident (Figure 1a, b) . Hematopoietic cells present at the beginning of the culture were never seen attached to the CFU-En, while proliferating fibroblast colonies appeared covered by lymphocytes and macrophages in these early phases of the culture. The absence of a selective medium and of specific growth factors allows the maintenance of reciprocal relationship between endothelial cells and the hematopoietic counterpart. In BM samples from remission phase where the rate of the CFU-F colonies is lower than at diagnosis CFU-En appeared isolated and after 20-30 days of culture (Figure 1c, d ) the addition of VEGF and ECGS in the medium allowed a discrete increase of the size of CFU-En and a concomitant activation of endothelial cells ( Figure  1e, f) ; however, after 40 days of culture the rate of proliferation was decreased.
Immunophenotypic analysis of BM CFU-En colonies
By using different MoAbs, we analyzed the phenotypic profile of 15-days cultured CFU-En as illustrated in Table 2 . CFU-En appear as large clusters (10-100 cells) of spindleshaped ECs as shown in Figure 1a . BM endothelial cells obtained from CFU-En were positive for several specific endothelial markers such as CD31 (Figure 1e ), CD105 (Figure 1f ), CD106, factor VIII (von Willebrand), and KDR (VEGF receptor 2); however, CD106 and KDR staining was weak. In particular, an intense punctate perinuclear staining of von Willebrand factor is visible while the expression of CD31 is characterized by typical intense membrane staining at points of cell-cell contact (Figure 1e ). ECs were negative for several markers which were strongly expressed on fibroblasts, such as CD68, CD44, and collagen I-II-III. BM ECs were found to be negative for anti-smooth-muscle-actin, CD10, and, interestingly, UPAR-r. ECs from CFU-En colonies were also found to be negative for class II-reacting CD34 MoAb. 19 Endothelial cells cultured in the presence of VEGF and ECGS displayed activated features such as bigger size and hairy expansions of the surface plasma membrane ( Figure  1e , f). Microparticles seem to shed from the plasma membrane of endothelial cells undergoing activation. Furthermore, stimulated ECs appears to be in contact by blebbing of the membrane surface.
Assessment of CFU-En at diagnosis
As far as the analysis of CFU-En is concerned, we found that the number of CFU-En/10 6 cells, evaluated after 15 days of culture (Figure 2) , was low in all samples obtained from newly diagnosed NHL patients (0.6771.4 s.d.), irrespective of the type of the clone (T vs B), the stage and the grade of the lymphoma, and the presence or absence of bone marrow involvement. These values were comparable to those observed in normal controls (0.4170.48 s.d.). However, at the time of diagnosis, the high-grade NHL (Figure 2c ) patients displayed the highest incidence of CFU-En colonies (1.0771.9 s.d.; P-value: not significant), even if the statistical analysis did not disclose Endothelial colonies in non-Hodgkin's lymphoma F Lanza et al any significant difference with the other histological subtypes.
Assessment of CFU-En in remission phase
Patients in remission phase after chemotherapy displayed significantly higher values of CFU-En/10 (Figure 2c ). When the data were analyzed according to the clinical stages of the patients, no significant differences in the incidence of CFU-En were seen between stages I-II and III-IV (Figure 2d ).
Assessment of CFU-En after PBSCT
As shown in Figure 2 , the mean number of endothelial cells-colonies was significantly reduced in the first (I: 1-4 months) and second period (5-9 months) after transplantation (0.5471.14 s.d., P ¼ 0.046; P ¼ 0.006 using the Bonferroni test), and 0.3870.96 s.d. (P ¼ 0.041; P ¼ 0.01, according to the Bonferron method), respectively, irrespective of the clinical features of the NHL, as compared with the pre-transplant period; at these time points CFU-En number was comparable to those observed at diagnosis. In the later phases after PBSCT, CFU-En values progressively increased in the third period (10-15 months: mean values of 1.572.9 s.d.) even if they never reached the incidence observed in patients who achieved the remission phase after chemotherapy, before PBSCT. At 20-22 months after PBSCT the incidence of CFU-En/10 6 cells tended to reach Endothelial colonies in non-Hodgkin's lymphoma F Lanza et al values similar to that displayed at diagnosis and in normal controls.
Short-term CFU-F assay
By using long-term culture, we also looked at the growth and the distribution of bone marrow mesenchymal precursors (CFU-F/10 6 cells) in NHL patients. As showed in Table 3 and Figure 2e , the number of CFU-F/10 6 cells at diagnosis was 10.9711.4 s.d. These values decrease in remission phase 8.5711.3 s.d. and increased 1 year after PBSCT, reaching values similar to that observed at diagnosis ( Table 3 ). The growth pattern of CFU-F was inversely correlated with that of CFU-En as shown in Figure 2e . 771.1 s.d.) . After PBSCT the CFU-GM/10 5 and BFU-E/10 5 colonies were decreased in the first period after transplantation (1-6 months), but these values tended to progressively increase in the later phases after transplantation (6-18 months) reaching values similar to that observed in remission state. No differences were observed in the incidence of CFU-GEMM/10 5 cells before and after PBSCT.
Correlation between CFU-En and clinical characteristics of NHL
No significant correlation was found between the number of bone marrow CFU-En and clinical parameters such as sex, age, type of chemotherapy, and BM involvement at diagnosis. Moreover, the statistical analysis showed that in patients in remission state, who underwent the PBSCT, the number of hematopoietic colonies such as CFU-GM/10 6 cells (respectively P ¼ 0.013 and P ¼ 0.044), while no correlation was observed between the incidence of BM endothelial colonies and that of CFU-F/10 6 cells.
Discussion
The establishment of human BM endothelial cell cultures has been considered particularly difficult because of the low number of ECs in the normal BM. In hematological malignancies, a few data are available in the literature concerning the incidence and the functional role of BM ECs. In recent years, based on the analysis of the MVD in fixed human BM biopsies and mouse models, some authors have investigated the presence of endothelial cells in relation to the angiogenesis process; [11] [12] [13] [14] [15] in some cases, angiogenesis has been found to be increased in MM, 11 AML, 13 and MDS. 15, 20 Moreover, it has been shown that the levels of some angiogenic factors such as VEGF could mediate leukemic cell proliferation, and thus may be considered prognostic factors in acute leukemia. 13, 21 As far as the analysis of NHL patients is concerned, high serum VEGF levels were associated with poor outcome 22 and circulating IL-6, VEGF and b-FGF (but not of endostatin, angiogenin, and leptin) might be considered prognostic factors in NHL. 23 In a previous study, we used an in vitro method to detect bone marrow endothelial cells in MM patients; this method was of clinical value, as it gave evidence that an increased number of endothelial colonies was correlated with disease progression and plasma cells proliferation capacity. 16 In this study, the CFU-En number in both untreated and DAV (Dexamethasone, Adryamycin, Vincristine)-treated MM patients was significantly higher than in normal bone marrow, in the melphalan group, and in monoclonal gammopathy of undetermined significance (MGUS) patients, thus confirming a role for these cells in bone marrow angiogenesis.
In this paper, as alternative to bone marrow biopsies analysis or angiogenesis related molecules detection, by using the previously published in vitro unselective endothelial cell culture assay, we assessed the spontaneous growth of endothelial colonies in patients with NHL with the aim of (i) evaluating the number and the distribution of CFUEn in relation to patients' clinical characteristics, and (ii) exploring the role played by endothelial cells in a pathological BM microenvironment. The results showed that the number of the CFU-En was significantly higher in samples collected in remission state after chemotherapy, in comparison with that detected in newly diagnosed patients and in normal controls. Interestingly, in the NHL subgroup who achieved a remission after chemotherapy, low-grade NHL patients were characterized by a higher CFU-En number in comparison with that observed in high-grade NHL. Our data further indicate that the number of CFUEn was comparable in B and T-NHL, but these data should be regarded as preliminary due to the low number of T-NHL patients examined in this study; moreover, the CFUEn number was not significantly influenced by the clinical stage of the disease. As far as the analysis of CFU-En in the transplant group is concerned, we demonstrated that number of CFU-En colonies was decreased in the first 4-6 months after PBSCT, irrespective of patient subgroups. However, CFU-En number returned to pre-transplant values 18-30 months after transplantation. Although variations in CFU-En number of patients analyzed after PBSCT were detected, it is interesting to underline that CFU-En values in the transplanted subgroup never reached the incidence of those patients who achieved a remission state after chemotherapy.
These findings are partially in contrast with our data collected in multiple myeloma patients, and seem to not support an association between bone marrow endothelial cell growth and disease progression. However, these results should be regarded as preliminary, as in vivo studies aimed at evaluating markers of angiogenesis such as microvessel density and VEGF measurement are lacking in our study.
As far as the analysis of another component of the BM microenvironment is concerned, 24 a decreased number of CFU-F was seen in NHL in the first 9 months after transplantation, in comparison with pre-transplant values. These data are in agreement with previous reports, showing a damage of the marrow microenvironment after bone marrow transplantation or the administration of cytostatic drugs. [25] [26] [27] Based on these data it can be said that in remission phase of NHL patients perturbations and physiological stress such as those that may occur in the BM after chemotherapy do not prevent the growth of endothelial cells in contrast to what happened to the fibroblast component of the BM. The persistence of ECs may contribute to the bone marrow hematopoietic reconstitution by producing potent stimulating factors such as b-FGF, which, under acidosis conditions, has been shown to stimulate EC proliferation and protection from apoptosis, 28 or VEGF that can be produced in larger amounts by repopulating progenitors, which can ultimately stimulate (by a paracrine loop) the proliferation of both immature (angioblasts) and differentiated endothelial cells. 29, 30 Furthermore, it must be said that some of these patients received radiotherapy, which can induce an upregulation of the E-9 protein (CD105) in human vascular endothelial cells. 31 Human bone marrow endothelial cells present in remission phase may also have the effect of protecting and maintaining the hematopoietic stem cell compartment from extensive differentiation through the production of differentiation inhibitors such as thymosin b4 and AcSDKP 32, 33 that has been shown to induce angiogenesis in vitro and in vivo. 34 On the other hand, other reports have shown that the existence of circulating BM endothelial progenitor cells can restore blood flow to ischemic animals leading to the concept of 'therapeutic adult vasculogenesis' that may explain the recruitment of ECs to various target organs such as BM, where they might contribute to the in situ neo-vascularization. [33] [34] [35] [36] [37] [38] [39] [40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33] [34] [35] [36] [37] [38] [39] [40] In conclusion,
Endothelial colonies in non-Hodgkin's lymphoma F Lanza et al our in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function. However, based on results on BM hematopoietic colony assays and on previously published papers the data here presented seem to suggest that human bone marrow endothelial cells could also be involved in mechanisms, which are different from tumor angiogenesis, such as hematopoietic cell preservation and physiological repair after chemotherapy. Although our data need to be confirmed with in vivo analyses of markers of angiogenesis before drawing any definitive conclusion on this subject, the in vitro assessment of CFU-En colonies could be considered an useful tool for a better comprehension of the multiple role played by ECs in the bone marrow microenvironment of hematological patients treated with chemotherapy and PBSCT.
